The primary objective of IMMUNOMARK-COV is to define an applicable immune signature predicting clinical worsening on COVID-19 patient admission in order to help physicians to take informed therapeutic decisions able to modify early the course of the disease.
Secondary objectives are:
* To assess the early dynamics of SARS-CoV-2-specific cellular immunity in patients followed longitudinally
* To assess the dynamics of gd T cells during COVID-19
* Transcriptomic analysis of discrete and functionally major T cell populations
* To assess SARS-CoV-2-specific humoral immunity in patients upon recovery
Identification of early predictive biomarkers of worsening of COVID-19 patients is of paramount importance. This goal is expected to be achieved through the fine analysis of circulating immune effectors, and their dynamics, in categories of patients with very different clinical outcomes.
To date, management of clinical worsening relies mainly on supportive care in ICU, leading to prolonged stay and saturation of facilities. Earlier therapeutic intervention based on identification of robust predictive biomarkers should:
* Help physicians to take therapeutic decisions
* Improve prognosis of patients that suffered from clinical worsening
* Prevent clinical worsening and transfer to ICU
* Improve the burden relying on ICU facilities in a setting of overflow
* Improve the prevention and management of COVID-19 patients to be able to face in a near future several other waves of COVID-19 Furthermore, identification of immune effectors implicated in tissular damages may also help to identify new therapeutic targets.
